NDAINHALATIONGAS
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
XENON XE 133 (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa]. First approved in 1976.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xenon XE-133 is an inhaled radioactive gas radiopharmaceutical used for pulmonary ventilation imaging. It enables physicians to visualize airflow patterns and detect ventilation defects in the lungs. The agent works by being inhaled and distributing throughout the respiratory system, allowing nuclear imaging to assess lung function.
LOE Approaching
This product is nearing loss of exclusivity with moderate competitive pressure (30/100), indicating a mature, stable but declining commercial opportunity with likely reduced team expansion.
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Xenon XE-133 offers specialized expertise in radiopharmaceutical quality assurance and regulatory compliance, with only 1 linked job currently available. This niche product provides deep technical knowledge but limited career growth trajectory given its mature lifecycle stage.
International License Partner Quality Specialist
Quality Assurance
Worked on XENON XE 133 at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.